Eyecare
logo alongside a box and single-dose vial of Beovu (brolucizumab-dbll) 6 mg/0.05 mL intravitreal injection, acquired for commercial distribution in Canada.
  • November 14, 2026
IMVIONIX Secures Canadian Rights to BEOVU for Wet AMD and Diabetic Macular Edema

IMVIONIX, a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, announced…

Continue reading